{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T15:33:10Z","timestamp":1775057590328,"version":"3.50.1"},"reference-count":42,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["oooojournal.net","clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.oooo.2023.12.793","type":"journal-article","created":{"date-parts":[[2024,1,9]],"date-time":"2024-01-09T01:40:13Z","timestamp":1704764413000},"page":"372-378","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Thalidomide for management of refractory oral mucosal diseases"],"prefix":"10.1016","volume":"137","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7949-336X","authenticated-orcid":false,"given":"Yuanming","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sook Bin","family":"Woo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathaniel S.","family":"Treister","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.oooo.2023.12.793_bib0001","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/bdrc.21096","article-title":"Thalidomide-induced teratogenesis: history and mechanisms","volume":"105","author":"Vargesson","year":"2015","journal-title":"Birth Defects Res C Embryo Today"},{"key":"10.1016\/j.oooo.2023.12.793_bib0002","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2165\/00002018-200629040-00003","article-title":"Thalidomide use in the US: experience with pregnancy testing in the S.T.E.P.S. programme","volume":"29","author":"Uhl","year":"2006","journal-title":"Drug Saf"},{"key":"10.1016\/j.oooo.2023.12.793_bib0003","unstructured":"U.S. Food and Drug Administration, (2024, February 16). Thalidomide (marketed as Thalomid) Information. https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/thalidomide-marketed-thalomid-information."},{"key":"10.1016\/j.oooo.2023.12.793_bib0004","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1007\/s11899-019-00536-6","article-title":"IMiDs new and old","volume":"14","author":"Yamshon","year":"2019","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.oooo.2023.12.793_bib0005","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1177\/107327480301000504","article-title":"Thalidomide and its derivatives: new promise for multiple myeloma","volume":"10","author":"Weber","year":"2003","journal-title":"Cancer Control"},{"key":"10.1016\/j.oooo.2023.12.793_bib0006","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1016\/S0140-6736(04)16308-3","article-title":"Thalidomide","volume":"363","author":"Franks","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.oooo.2023.12.793_bib0007","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.biopha.2012.03.005","article-title":"Thalidomide for improving cutaneous and pulmonary sarcoidosis in patients resistant or with contraindications to corticosteroids","volume":"66","author":"Fazzi","year":"2012","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.oooo.2023.12.793_bib0008","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1001\/jamadermatol.2021.4083","article-title":"Evaluation of thalidomide treatment of patients with chronic erythema multiforme: a multicenter retrospective cohort study","volume":"157","author":"Roux","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.oooo.2023.12.793_bib0009","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1067\/moe.2002.113","article-title":"Thalidomide for the treatment of recalcitrant oral Crohn's disease and orofacial granulomatosis","volume":"95","author":"Hegarty","year":"2003","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"10.1016\/j.oooo.2023.12.793_bib0010","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/bjd.12944","article-title":"Thalidomide in the treatment of refractory orofacial granulomatosis","volume":"171","author":"Eustace","year":"2014","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.oooo.2023.12.793_bib0011","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/0030-4220(87)90006-5","article-title":"Recurrent aphthous stomatitis of the Behcet's type: successful treatment with thalidomide","volume":"64","author":"Eisenbud","year":"1987","journal-title":"Oral Surg Oral Med Oral Pathol"},{"key":"10.1016\/j.oooo.2023.12.793_bib0012","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1001\/archderm.1990.01670310085012","article-title":"Crossover study of thalidomide vs placebo in severe recurrent aphthous stomatitis","volume":"126","author":"Revuz","year":"1990","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.oooo.2023.12.793_bib0013","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1159\/000246279","article-title":"Thalidomide and recurrent aphthous stomatitis: a follow-up study","volume":"193","author":"Bonnetblanc","year":"1996","journal-title":"Dermatology"},{"key":"10.1016\/j.oooo.2023.12.793_bib0014","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/MD.0b013e3181dfca14","article-title":"Use of thalidomide for severe recurrent aphthous stomatitis: a multicenter cohort analysis","volume":"89","author":"Hello","year":"2010","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.oooo.2023.12.793_bib0015","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/jop.13259","article-title":"A randomized controlled clinical trial on dose optimization of thalidomide in maintenance treatment for recurrent aphthous stomatitis","volume":"51","author":"Deng","year":"2022","journal-title":"J Oral Pathol Med"},{"key":"10.1016\/j.oooo.2023.12.793_bib0016","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1111\/jop.12960","article-title":"The efficacy and safety of thalidomide on the recurrence interval of continuous recurrent aphthous ulceration: a randomized controlled clinical trial","volume":"49","author":"Zeng","year":"2020","journal-title":"J Oral Pathol Med"},{"key":"10.1016\/j.oooo.2023.12.793_bib0017","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.oooo.2020.06.009","article-title":"Thalidomide use in the management of oromucosal disease: a 10-year review of safety and efficacy in 12 patients","volume":"130","author":"Harte","year":"2020","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"10.1016\/j.oooo.2023.12.793_bib0018","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1086\/314834","article-title":"Thalidomide for the treatment of esophageal aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group","volume":"180","author":"Jacobson","year":"1999","journal-title":"J Infect Dis"},{"key":"10.1016\/j.oooo.2023.12.793_bib0019","first-page":"169","article-title":"Thalidomide for treatment of oral aphthous ulcers in patients with human immunodeficiency virus: case report and review","volume":"92","author":"Ball","year":"1997","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.oooo.2023.12.793_bib0020","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1056\/NEJM199705223362103","article-title":"Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group","volume":"336","author":"Jacobson","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.oooo.2023.12.793_bib0021","doi-asserted-by":"crossref","first-page":"443","DOI":"10.7326\/0003-4819-128-6-199803150-00004","article-title":"Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome. A randomized, double-blind, placebo-controlled trial","volume":"128","author":"Hamuryudan","year":"1998","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.oooo.2023.12.793_bib0022","first-page":"S129","article-title":"TNF-alpha antagonists and thalidomide for the management of gastrointestinal Beh\u00e7et's syndrome refractory to the conventional treatment modalities: a case series and review of the literature","volume":"33","author":"Hatemi","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.oooo.2023.12.793_bib0023","unstructured":"Bristol-Myers Squibb Company (2024, February 16). THALOMID REMS program. https:\/\/www.thalomidrems.com\/index.html."},{"key":"10.1016\/j.oooo.2023.12.793_bib0024","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/j.1365-2133.2005.06747.x","article-title":"Thalidomide: dermatological indications, mechanisms of action and side-effects","volume":"153","author":"Wu","year":"2005","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.oooo.2023.12.793_bib0025","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/DAD.0b013e3181e26db0","article-title":"Traumatic ulcerative granuloma with stromal eosinophilia: a lesion with alarming histopathologic presentation and benign clinical course","volume":"33","author":"Gagari","year":"2011","journal-title":"Am J Dermatopathol"},{"key":"10.1016\/j.oooo.2023.12.793_bib0026","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.4103\/jomfp.JOMFP_321_20","article-title":"Traumatic ulcerative granuloma with stromal eosinophilia: a puzzle","volume":"25","author":"Lakkam","year":"2021","journal-title":"J Oral Maxillofac Pathol"},{"key":"10.1016\/j.oooo.2023.12.793_bib0027","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.adaj.2020.08.020","article-title":"A painful ulceration of the buccal mucosa","volume":"152","author":"Vargo","year":"2021","journal-title":"J Am Dent Assoc"},{"key":"10.1016\/j.oooo.2023.12.793_bib0028","doi-asserted-by":"crossref","first-page":"e338","DOI":"10.1093\/rheumatology\/kead294","article-title":"Lenalidomide for treatment of refractory aphthosis and neutrophilic pustulosis in familial pyrin-associated autoinflammation with neutrophilic dermatosis","volume":"62","author":"Poujade","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.oooo.2023.12.793_bib0029","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/RHU.0000000000000100","article-title":"Successful management of refractory pediatric-onset complex aphthosis with lenalidomide","volume":"20","author":"Kalampokis","year":"2014","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.oooo.2023.12.793_bib0030","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/RHU.0000000000001160","article-title":"Thalidomide and lenalidomide for refractory systemic\/cutaneous lupus erythematosus treatment: a narrative review of literature for clinical practice","volume":"27","author":"Yuki","year":"2021","journal-title":"J Clin Rheumatol"},{"key":"10.1016\/j.oooo.2023.12.793_bib0031","doi-asserted-by":"crossref","first-page":"144","DOI":"10.2174\/187221310791163026","article-title":"Pharmacological properties of thalidomide and its analogues","volume":"4","author":"De Sanctis","year":"2010","journal-title":"Recent Pat Inflamm Allergy Drug Discov"},{"key":"10.1016\/j.oooo.2023.12.793_bib0032","doi-asserted-by":"crossref","first-page":"153","DOI":"10.5045\/kjh.2011.46.3.153","article-title":"Treatment of chronic graft-versus-host disease: past, present and future","volume":"46","author":"Martin","year":"2011","journal-title":"Korean J Hematol"},{"key":"10.1016\/j.oooo.2023.12.793_bib0033","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/bmt.2012.76","article-title":"Chronic GVHD: Where are we? Where do we want to be? Will immunomodulatory drugs help?","volume":"48","author":"Linhares","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.oooo.2023.12.793_bib0034","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbmt.2010.05.011","article-title":"Consensus Conference on Clinical Practice in Chronic GVHD: second-line treatment of chronic graft-versus-host disease","volume":"17","author":"Wolff","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.oooo.2023.12.793_bib0035","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1182\/blood.2020006892","article-title":"A randomized phase 2 trial of pomalidomide in subjects failing prior therapy for chronic graft-versus-host disease","volume":"137","author":"Curtis","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.oooo.2023.12.793_bib0036","doi-asserted-by":"crossref","first-page":"4825","DOI":"10.1007\/s00520-016-3337-5","article-title":"Chronic oral mucositis after radiotherapy to the head and neck: a new insight","volume":"24","author":"Elad","year":"2016","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.oooo.2023.12.793_bib0037","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1111\/odi.12710","article-title":"Oral complications at 6 months after radiation therapy for head and neck cancer","volume":"23","author":"Lalla","year":"2017","journal-title":"Oral Dis"},{"key":"10.1016\/j.oooo.2023.12.793_bib0038","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1002\/cncr.34074","article-title":"Efficacy and safety of thalidomide in preventing oral mucositis in patients with nasopharyngeal carcinoma undergoing concurrent chemoradiotherapy: a multicenter, open-label, randomized controlled trial","volume":"128","author":"Liang","year":"2022","journal-title":"Cancer"},{"key":"10.1016\/j.oooo.2023.12.793_bib0039","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s40487-021-00168-y","article-title":"Chemotherapy-induced peripheral neuropathy: epidemiology, pathomechanisms and treatment","volume":"9","author":"Burgess","year":"2021","journal-title":"Oncol Ther"},{"key":"10.1016\/j.oooo.2023.12.793_bib0040","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1136\/ard.53.12.828","article-title":"Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behcet's disease: use of neurophysiological studies to detect thalidomide neuropathy","volume":"53","author":"Gardner-Medwin","year":"1994","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.oooo.2023.12.793_bib0041","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1111\/bjd.20968","article-title":"Validation of an Oral Disease Severity Score for use in oral lichen planus","volume":"186","author":"Ormond","year":"2022","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.oooo.2023.12.793_bib0042","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1111\/j.1600-0714.2011.01021.x","article-title":"Validity and reliability of a newly developed quality of life questionnaire for patients with chronic oral mucosal diseases","volume":"40","author":"Ni Riordain","year":"2011","journal-title":"J Oral Pathol Med"}],"container-title":["Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212440324000051?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212440324000051?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,4,3]],"date-time":"2024-04-03T23:21:14Z","timestamp":1712186474000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212440324000051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S2212440324000051"],"URL":"https:\/\/doi.org\/10.1016\/j.oooo.2023.12.793","relation":{},"ISSN":["2212-4403"],"issn-type":[{"value":"2212-4403","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Thalidomide for management of refractory oral mucosal diseases","name":"articletitle","label":"Article Title"},{"value":"Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oooo.2023.12.793","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}